Advances in the therapy of Alzheimer's disease: Targeting amyloid beta and tau and perspectives for the future

Harald Hampel, Lon S. Schneider, Ezio Giacobini, Miia Kivipelto, Shireen Sindi, Bruno Dubois, Karl Broich, Robert Nisticò, Paul S. Aisen, Simone Lista

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Worldwide multidisciplinary translational research has led to a growing knowledge of the genetics and molecular pathogenesis of Alzheimer's disease (AD) indicating that pathophysiological brain alterations occur decades before clinical signs and symptoms of cognitive decline can be diagnosed. Consequently, therapeutic concepts and targets have been increasingly focused on early-stage illness before the onset of dementia; and distinct classes of compounds are now being tested in clinical trials. At present, there is a growing consensus that therapeutic progress in AD delaying disease progression would significantly decrease the expanding global burden. The evolving hypothesis-and evidence-based generation of new diagnostic research criteria for early-stage AD has positively impacted the development of clinical trial designs and the characterization of earlier and more specific target populations for trials in prodromal as well as in pre-and asymptomatic at-risk stages of AD.

Original languageEnglish
Pages (from-to)83-105
Number of pages23
JournalExpert Review of Neurotherapeutics
Volume15
Issue number1
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Amyloid
Alzheimer Disease
Clinical Trials
Translational Medical Research
Health Services Needs and Demand
Therapeutics
Signs and Symptoms
Dementia
Disease Progression
Molecular Biology
Consensus
Brain
Research

Keywords

  • Alzheimer's disease
  • amyloid beta immunotherapy
  • bapineuzumab
  • biological markers
  • clinical trials
  • prevention
  • randomized controlled trials
  • solanezumab
  • systems biology
  • Tau immunotherapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Advances in the therapy of Alzheimer's disease : Targeting amyloid beta and tau and perspectives for the future. / Hampel, Harald; Schneider, Lon S.; Giacobini, Ezio; Kivipelto, Miia; Sindi, Shireen; Dubois, Bruno; Broich, Karl; Nisticò, Robert; Aisen, Paul S.; Lista, Simone.

In: Expert Review of Neurotherapeutics, Vol. 15, No. 1, 01.01.2014, p. 83-105.

Research output: Contribution to journalArticle

Hampel, H, Schneider, LS, Giacobini, E, Kivipelto, M, Sindi, S, Dubois, B, Broich, K, Nisticò, R, Aisen, PS & Lista, S 2014, 'Advances in the therapy of Alzheimer's disease: Targeting amyloid beta and tau and perspectives for the future', Expert Review of Neurotherapeutics, vol. 15, no. 1, pp. 83-105. https://doi.org/10.1586/14737175.2015.995637
Hampel, Harald ; Schneider, Lon S. ; Giacobini, Ezio ; Kivipelto, Miia ; Sindi, Shireen ; Dubois, Bruno ; Broich, Karl ; Nisticò, Robert ; Aisen, Paul S. ; Lista, Simone. / Advances in the therapy of Alzheimer's disease : Targeting amyloid beta and tau and perspectives for the future. In: Expert Review of Neurotherapeutics. 2014 ; Vol. 15, No. 1. pp. 83-105.
@article{16a4e9d3940f490b987186a260b9da38,
title = "Advances in the therapy of Alzheimer's disease: Targeting amyloid beta and tau and perspectives for the future",
abstract = "Worldwide multidisciplinary translational research has led to a growing knowledge of the genetics and molecular pathogenesis of Alzheimer's disease (AD) indicating that pathophysiological brain alterations occur decades before clinical signs and symptoms of cognitive decline can be diagnosed. Consequently, therapeutic concepts and targets have been increasingly focused on early-stage illness before the onset of dementia; and distinct classes of compounds are now being tested in clinical trials. At present, there is a growing consensus that therapeutic progress in AD delaying disease progression would significantly decrease the expanding global burden. The evolving hypothesis-and evidence-based generation of new diagnostic research criteria for early-stage AD has positively impacted the development of clinical trial designs and the characterization of earlier and more specific target populations for trials in prodromal as well as in pre-and asymptomatic at-risk stages of AD.",
keywords = "Alzheimer's disease, amyloid beta immunotherapy, bapineuzumab, biological markers, clinical trials, prevention, randomized controlled trials, solanezumab, systems biology, Tau immunotherapy",
author = "Harald Hampel and Schneider, {Lon S.} and Ezio Giacobini and Miia Kivipelto and Shireen Sindi and Bruno Dubois and Karl Broich and Robert Nistic{\`o} and Aisen, {Paul S.} and Simone Lista",
year = "2014",
month = "1",
day = "1",
doi = "10.1586/14737175.2015.995637",
language = "English",
volume = "15",
pages = "83--105",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Advances in the therapy of Alzheimer's disease

T2 - Targeting amyloid beta and tau and perspectives for the future

AU - Hampel, Harald

AU - Schneider, Lon S.

AU - Giacobini, Ezio

AU - Kivipelto, Miia

AU - Sindi, Shireen

AU - Dubois, Bruno

AU - Broich, Karl

AU - Nisticò, Robert

AU - Aisen, Paul S.

AU - Lista, Simone

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Worldwide multidisciplinary translational research has led to a growing knowledge of the genetics and molecular pathogenesis of Alzheimer's disease (AD) indicating that pathophysiological brain alterations occur decades before clinical signs and symptoms of cognitive decline can be diagnosed. Consequently, therapeutic concepts and targets have been increasingly focused on early-stage illness before the onset of dementia; and distinct classes of compounds are now being tested in clinical trials. At present, there is a growing consensus that therapeutic progress in AD delaying disease progression would significantly decrease the expanding global burden. The evolving hypothesis-and evidence-based generation of new diagnostic research criteria for early-stage AD has positively impacted the development of clinical trial designs and the characterization of earlier and more specific target populations for trials in prodromal as well as in pre-and asymptomatic at-risk stages of AD.

AB - Worldwide multidisciplinary translational research has led to a growing knowledge of the genetics and molecular pathogenesis of Alzheimer's disease (AD) indicating that pathophysiological brain alterations occur decades before clinical signs and symptoms of cognitive decline can be diagnosed. Consequently, therapeutic concepts and targets have been increasingly focused on early-stage illness before the onset of dementia; and distinct classes of compounds are now being tested in clinical trials. At present, there is a growing consensus that therapeutic progress in AD delaying disease progression would significantly decrease the expanding global burden. The evolving hypothesis-and evidence-based generation of new diagnostic research criteria for early-stage AD has positively impacted the development of clinical trial designs and the characterization of earlier and more specific target populations for trials in prodromal as well as in pre-and asymptomatic at-risk stages of AD.

KW - Alzheimer's disease

KW - amyloid beta immunotherapy

KW - bapineuzumab

KW - biological markers

KW - clinical trials

KW - prevention

KW - randomized controlled trials

KW - solanezumab

KW - systems biology

KW - Tau immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84920765407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920765407&partnerID=8YFLogxK

U2 - 10.1586/14737175.2015.995637

DO - 10.1586/14737175.2015.995637

M3 - Article

C2 - 25537424

AN - SCOPUS:84920765407

VL - 15

SP - 83

EP - 105

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 1

ER -